Inventor
ZHUOZHI WANG
Inventor
CN
Overview
Patents· 6 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
C07Kprimary
C07KPeptides26%
A61KPreparations for medical, dental or toiletry purposes22%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations22%
C12NMicroorganisms or enzymes22%
G01NInvestigating or analysing materials by determining their chemical or physical properties9%
PatentTitleYear
12,240,906Monoclonal antibodies to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)202511,845,796Bispecific polypeptide complexes202311,643,463Monoclonal antibodies to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)202311,414,487Monoclonal antibodies to programmed death 1 (PD-1)202211,365,254Bispecific CD3/CD19 polypeptide complexes2022RE049099Humanized monoclonal antibodies against activated protein c and uses thereof2022Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2022–2023Patents assigned to WUXI BIOLOGICS IRELAND LTD (2)· patent assignee history
2022Patents assigned to BAYER HEALTHCARE LLC (1)· patent assignee history
2022Patents assigned to CSTONE PHARMACEUTICALS (1)· patent assignee history
2022Patents assigned to CSTONE PHARMACEUTICALS SHANGHAI CO LTD (1)· patent assignee history
2022–2025Based in CN· patent location history
2022Based in US· patent location history
2023–2025Patents assigned to WUXI BIOLOGICS SHANGHAI CO LTD (2)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| WUXI BIOLOGICS IRELAND LTD | 2 | 2022–2023 |
| WUXI BIOLOGICS SHANGHAI CO LTD | 2 | 2023–2025 |
| BAYER HEALTHCARE LLC | 1 | 2022 |
| CSTONE PHARMACEUTICALS | 1 | 2022 |
| CSTONE PHARMACEUTICALS SHANGHAI CO LTD | 1 | 2022 |
Locations
| Location | Patents | Span |
|---|---|---|
| CN | 4 | 2022–2025 |
| US | 2 | 2022 |